tert-butyl (S)-3-hydroxy-3,6-dihydropyridine-1(2H)-carboxylate | 780782-28-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: tert-butyl (S)-3-hydroxy-3,6-dihydropyridine-1(2H)-carboxylate
• 英文别名: tert-butyl (3S)-3-hydroxy-1,2,3,6-tetrahydropyridine-1-carboxylate；tert-butyl (3S)-3-hydroxy-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 780782-28-7
• 化学式: C₁₀H₁₇NO₃
• 分子量: 199.25
• InChiKey: NICJOYHYEDFTIX-QMMMGPOBSA-N

物化性质

• 熔点：
  70-71 °C(Solv: hexane (110-54-3))
• 沸点：
  295.9±40.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-3-hydroxy-3,6-dihydropyridine-1(2H)-carboxylate 在 四氧化锇 咪唑 、 盐酸 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 sodium periodate 、 Oxone 、 1,1,1-三氟丙酮 、 三氟化硼乙醚 、 edetate disodium 作用下， 以 1,4-二氧六环 、 乙醚 、 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 7.0h， 生成 (3R,4R,5R)-5-(羟基甲基)哌啶-3,4-二醇盐酸盐
  参考文献：
  名称：

  A short and concise synthesis of isofagomine, homoisofagomine, and 5′-deoxyisofagomine

  摘要：

  A short and concise synthesis of isofagomine derivatives via the epoxidation of chiral N-Boc-5-hydroxy-3-piperidene, followed by regioselective epoxide ring opening is described. This constitutes the first reported synthesis of homoisofagomine and the 5'-deoxyisofagomine. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.07.127
• 作为产物：
  描述：

  tert-butyl (S)-allyl(2-hydroxybut-3-en-1-yl)carbamate 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 作用下， 以 二氯甲烷 为溶剂， 以5.2 g的产率得到tert-butyl (S)-3-hydroxy-3,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  发现一种抑制人肠道细菌厌氧胆碱代谢的环状胆碱类似物

  摘要：

  人类肠道微生物群将胆碱厌氧转化为三甲胺 (TMA) 与多种人类疾病有关。这种微生物代谢活动对宿主健康的潜在影响激发了多种努力来确定小分子抑制剂。在这里，我们使用有关细菌酶胆碱 TMA 裂解酶 (CutC) 的结构和机制的信息来开发一种环状胆碱类似物，可抑制细菌全细胞和复杂肠道微生物群落中胆碱向 TMA 的转化。体外生化分析和晶体结构表明这种类似物是一种竞争性的、基于机制的抑制剂。这项工作证明了基于结构的设计从人类肠道微生物群中获取自由基酶抑制剂的实用性。

  DOI：

  10.1021/acsmedchemlett.0c00005

文献信息

• [EN] CHOLINE METABOLISM INHIBITORS<br/>[FR] INHIBITEURS DU MÉTABOLISME DE LA CHOLINE
  申请人：HARVARD COLLEGE

  公开号：WO2020117942A1

  公开（公告）日：2020-06-11

  The present disclosure relates to compounds, compositions and methods for inhibiting choline metabolism, e.g., conversion of choline to trimethylamine. Disclosed herein are compounds, compositions, and methods for inhibiting choline metabolism, e.g., conversion of choline to TMA. Also disclosed herein are compounds, methods and compositions for inhibiting choline metabolism by gut microbiota resulting in reduction in the formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO).

  本公开涉及抑制胆碱代谢的化合物、组合物和方法，例如抑制胆碱转化为三甲胺的过程。本文披露了用于抑制胆碱代谢的化合物、组合物和方法，例如抑制胆碱转化为TMA。本文还披露了通过肠道微生物抑制胆碱代谢的化合物、方法和组合物，从而减少三甲胺（TMA）和三甲胺N-氧化物（TMAO）的形成。
• A New Route to Diverse 1-Azasugars from <i>N</i>-Boc-5-hydroxy-3-piperidene as a Common Building Block
  作者：Hidekazu Ouchi、Yukiko Mihara、Hiroki Takahata

  DOI：10.1021/jo050519j

  日期：2005.6.1

  for the synthesis of a variety of 1-azasugars with a nitrogen atom at the anomeric position is described. The readily available chiral N-Boc-5-hydroxy-3-piperidene 3 is transformed to isofagomine (2), homoisofagomine (13), and 5‘-deoxyisofagomine (14) via stereoselective epoxidation and regioselective ring-cleavage in a highly stereocontrolled manner. In addition, the synthesis of all four stereoisomers

  描述了一种合成具有异头位置氮原子的各种1-氮杂双胍的新的通用方法。易于获得的手性N -Boc-5-羟基-3-哌啶3通过立体选择性环氧化和区域选择性环裂解，以高度立体可控的方式转化为异黄花碱（2），高异黄花碱（13）和5'-脱氧异黄花碱（14）。 。此外，3,4,5- trihydroxypiperidines（所有四种立体异构体的合成18 - 21）被划分为1-azasugar型葡糖苷酶抑制剂是立体选择性地从（手性）啶实现3。
• Docking and SAR studies of d- and l-isofagomine isomers as human β-glucocerebrosidase inhibitors
  作者：Atsushi Kato、Saori Miyauchi、Noriko Kato、Robert J. Nash、Yuichi Yoshimura、Izumi Nakagome、Shuichi Hirono、Hiroki Takahata、Isao Adachi

  DOI：10.1016/j.bmc.2011.04.011

  日期：2011.6

  We report the structure-activity relationship of a series of D-, and L-isofagomine and fagomine isomers as glycosidase inhibitors. Our study revealed that a positive charge at the anomeric position of D-isofagomines enhanced the potency toward beta-glycosidases, while the epimerization at the C3 OH group drastically reduced their inhibitory potency by over three orders of magnitude. Furthermore, D-3,4-di-epi-isofagomine abolished their inhibition activities against all enzymes. L-Isofagomine was also a fairly potent inhibitor of human beta-glucocerebrosidase, with an IC50 value of 8.7 mu M. A molecular docking study revealed that the positions and orientations of the piperidine ring of D-3-epi-isofagomine in the binding site was similar to that of D-isofagomine, while D-3-epi-isofagomine missed the hydrogen bond interactions between Asp127 and the 3-OH group and between Trp179 and the 3-OH group. Furthermore, the top 10 docking models ranked by IFDscore suggested that D-3,4-di-epi-isofagomine can not bind to beta-glucocerebrosidase at a stable interaction mode. These results provide an insight into the structural requirements of isofagomine isomers for developing a new type of pharmacological chaperone for Gaucher disease. (C) 2011 Elsevier Ltd. All rights reserved.